Skip to main content
. 2018 Jul 11;38(28):6247–6266. doi: 10.1523/JNEUROSCI.3017-17.2018

Figure 6.

Figure 6.

NOS3 inhibition promotes young axon function recovery following OGD. A, The NOS1 inhibitor 3Br7NI showed maximum protection with pretreatment (cyan) at 30 μm. Post-treatment (magenta) was not protective at any dose tested. B, In young WM, 3Br7NI (30 μm) pretreatment preserved axon function during OGD and improved axon function recovery following OGD; post-treatment was not protective. n = number of MONs. *p < 0.05, **p < 0.01; one-way ANOVA followed by Bonferonni's post hoc test. C, The NOS2 inhibitor SMT showed maximum protection with pretreatment (cyan) at 10 μm. Post-treatment (magenta) was not protective at any dose tested. D, In young WM, SMT (10 μm) pretreatment preserved axon function during OGD and improved axon function recovery following OGD; post-treatment was not protective. n = number of MONs. *p < 0.05, **p < 0.01; one-way ANOVA followed by Bonferonni's post hoc test. E, The NOS3 inhibitor l-NIO showed maximum protection with pretreatment (cyan) at 1 μm. Remarkably, l-NIO 1 μm treatment post-OGD (magenta) also provided protection. F, In young WM, l-NIO (1 μm) pretreatment and post-treatment improved axon function recovery following OGD. n = number of MONs. *p < 0.05, **p < 0.01; one-way ANOVA followed by Bonferonni's post hoc test.